Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model

HSK7653, an oral dipeptidyl peptidase-4 inhibitor administered every 2 weeks, is a candidate for the treatment of type 2 diabetes mellitus. The major elimination pathway of HSK7653 in vivo is renal excretion, and hepatic metabolism and fecal excretion of unchanged compound contribute less to the sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Miao, Zhang, Shudong, Yu, Zhiheng, Yao, Xueting, Lei, Zihan, Yan, Pangke, Wu, Nan, Wang, Xu, Hu, Qin, Liu, Dongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science B.V 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485820/
https://www.ncbi.nlm.nih.gov/pubmed/37532063
http://dx.doi.org/10.1016/j.ejps.2023.106553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485820/
https://www.ncbi.nlm.nih.gov/pubmed/37532063
http://dx.doi.org/10.1016/j.ejps.2023.106553

Ejemplares similares